AU2013216870B2 - Compounds for treating spinal muscular atrophy - Google Patents
Compounds for treating spinal muscular atrophy Download PDFInfo
- Publication number
- AU2013216870B2 AU2013216870B2 AU2013216870A AU2013216870A AU2013216870B2 AU 2013216870 B2 AU2013216870 B2 AU 2013216870B2 AU 2013216870 A AU2013216870 A AU 2013216870A AU 2013216870 A AU2013216870 A AU 2013216870A AU 2013216870 B2 AU2013216870 B2 AU 2013216870B2
- Authority
- AU
- Australia
- Prior art keywords
- pyrido
- pyrimidin
- pyrazin
- methyl
- pyridin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active, expires
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2017204248A AU2017204248B2 (en) | 2012-02-10 | 2017-06-22 | Compounds for treating spinal muscular atrophy |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261597523P | 2012-02-10 | 2012-02-10 | |
| US61/597,523 | 2012-02-10 | ||
| PCT/US2013/025292 WO2013119916A2 (en) | 2012-02-10 | 2013-02-08 | Compounds for treating spinal muscular atrophy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2017204248A Division AU2017204248B2 (en) | 2012-02-10 | 2017-06-22 | Compounds for treating spinal muscular atrophy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2013216870A1 AU2013216870A1 (en) | 2014-08-28 |
| AU2013216870B2 true AU2013216870B2 (en) | 2017-07-20 |
Family
ID=48948163
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2013216870A Active 2036-06-02 AU2013216870B2 (en) | 2012-02-10 | 2013-02-08 | Compounds for treating spinal muscular atrophy |
| AU2017204248A Active AU2017204248B2 (en) | 2012-02-10 | 2017-06-22 | Compounds for treating spinal muscular atrophy |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2017204248A Active AU2017204248B2 (en) | 2012-02-10 | 2017-06-22 | Compounds for treating spinal muscular atrophy |
Country Status (29)
| Country | Link |
|---|---|
| US (6) | US9586955B2 (enExample) |
| EP (2) | EP3406252B1 (enExample) |
| JP (2) | JP6092897B2 (enExample) |
| KR (2) | KR102137087B1 (enExample) |
| CN (3) | CN108299314B (enExample) |
| AR (1) | AR092794A1 (enExample) |
| AU (2) | AU2013216870B2 (enExample) |
| BR (1) | BR112014019750B1 (enExample) |
| CA (1) | CA2863874C (enExample) |
| CL (1) | CL2014002100A1 (enExample) |
| CO (1) | CO7061082A2 (enExample) |
| CR (1) | CR20140376A (enExample) |
| DK (1) | DK2812004T3 (enExample) |
| EA (2) | EA029542B1 (enExample) |
| EC (1) | ECSP14017269A (enExample) |
| ES (1) | ES2697174T3 (enExample) |
| HU (1) | HUE039779T2 (enExample) |
| IL (2) | IL233959A (enExample) |
| MA (1) | MA35920B1 (enExample) |
| MX (2) | MX354074B (enExample) |
| NZ (1) | NZ628186A (enExample) |
| PE (1) | PE20142364A1 (enExample) |
| PH (2) | PH12018501711B1 (enExample) |
| PL (1) | PL2812004T3 (enExample) |
| SG (2) | SG11201404713PA (enExample) |
| TR (1) | TR201813877T4 (enExample) |
| TW (2) | TWI585085B (enExample) |
| UA (1) | UA116981C2 (enExample) |
| WO (1) | WO2013119916A2 (enExample) |
Families Citing this family (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10327940B2 (en) | 2008-11-09 | 2019-06-25 | 3D Systems, Inc. | Spiral brace |
| MX352861B (es) | 2011-12-30 | 2017-12-13 | Ptc Therapeutics Inc | Compuestos para tratar la atrofia muscular espinal. |
| MX357834B (es) | 2012-01-26 | 2018-07-26 | Ptc Therapeutics Inc | Compuestos de tipo isocumarina sustituidos para tratar la atrofia muscular espinal. |
| EP3406252B1 (en) * | 2012-02-10 | 2020-05-13 | PTC Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
| US9371336B2 (en) | 2012-03-01 | 2016-06-21 | Ptc Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
| EP2828247B1 (en) | 2012-03-23 | 2019-01-16 | PTC Therapeutics, Inc. | 4h-chromen-4-one derivatives for treating spinal muscular atrophy |
| JP2016503051A (ja) * | 2012-12-24 | 2016-02-01 | ラモット・アット・テル−アヴィヴ・ユニヴァーシティ・リミテッド | ナンセンス変異に起因する遺伝性疾患を治療する作用剤、及びこれを同定する方法 |
| CA2915764A1 (en) | 2013-08-19 | 2015-02-26 | F. Hoffmann-La Roche Ag | Screening method |
| WO2015105657A1 (en) * | 2013-12-19 | 2015-07-16 | Ptc Therapeutics, Inc. | Methods for modulating the amount of rna transcripts |
| AU2015261046C1 (en) | 2014-05-15 | 2019-07-25 | F. Hoffmann-La Roche Ag | Compounds for treating spinal muscular atrophy |
| US10882868B2 (en) | 2014-05-15 | 2021-01-05 | Hoffmann-La Roche Inc. | Compounds for treating spinal muscular atrophy |
| GB201410693D0 (en) | 2014-06-16 | 2014-07-30 | Univ Southampton | Splicing modulation |
| WO2016040748A1 (en) | 2014-09-12 | 2016-03-17 | Ionis Pharmaceuticals, Inc. | Compositions and methods for detection of smn protein in a subject and treatment of a subject |
| CN107109411B (zh) | 2014-10-03 | 2022-07-01 | 冷泉港实验室 | 核基因输出的定向增加 |
| BR112017008867A2 (pt) * | 2014-11-01 | 2017-12-26 | Chongqing Fochon Pharmaceutical Co Ltd | inibidores de proteína quinases |
| EP3242763A4 (en) * | 2015-01-05 | 2018-08-29 | Sikorsky Aircraft Corporation | Integrated vibration damper for additively manufactured structure and method |
| EP3298017B1 (en) | 2015-05-20 | 2019-08-14 | H. Hoffnabb-La Roche Ag | Compounds for treating spinal muscular atrophy |
| EP3310169B1 (en) | 2015-05-30 | 2023-05-17 | PTC Therapeutics, Inc. | Methods for modulating rna splicing |
| CN108603230A (zh) | 2015-10-09 | 2018-09-28 | 南安普敦大学 | 基因表达的调节与蛋白质表达失调的筛选 |
| AR106652A1 (es) * | 2015-11-12 | 2018-02-07 | Hoffmann La Roche | Compuestos para tratar la esclerosis lateral amiotrófica |
| AU2016353961B2 (en) * | 2015-11-12 | 2019-08-29 | F. Hoffmann-La Roche Ag | Compositions for treating spinal muscular atrophy |
| ES2821010T3 (es) | 2015-12-09 | 2021-04-23 | Cadent Therapeutics Inc | Moduladores heteroaromáticos del receptor NMDA y usos de los mismos |
| CA3119019C (en) | 2015-12-10 | 2024-06-11 | Ptc Therapeutics, Inc. | Compounds and methods for treating huntington's disease |
| EP3386978B1 (en) | 2015-12-10 | 2021-01-27 | H. Hoffnabb-La Roche Ag | Bridged piperidine derivatives |
| US11096956B2 (en) | 2015-12-14 | 2021-08-24 | Stoke Therapeutics, Inc. | Antisense oligomers and uses thereof |
| CN116059236A (zh) | 2015-12-14 | 2023-05-05 | 冷泉港实验室 | 用于治疗常染色体显性精神发育迟滞5型和Dravet综合征的反义寡聚体 |
| CN108473510B (zh) | 2016-04-28 | 2021-10-29 | 豪夫迈·罗氏有限公司 | 制备2-吡唑并[1,5-a]吡嗪-2-基吡啶并[1,2-a]嘧啶-4-酮的方法 |
| US11198867B2 (en) | 2016-06-16 | 2021-12-14 | Ionis Pharmaceuticals, Inc. | Combinations for the modulation of SMN expression |
| JP2019535789A (ja) * | 2016-11-28 | 2019-12-12 | ピーティーシー セラピューティクス，インコーポレーテッド | Ｒｎａスプライシングを調節する方法 |
| AU2017382339B2 (en) * | 2016-12-22 | 2024-02-15 | Novartis Ag | NMDA receptor modulators and uses thereof |
| EP4151627A1 (en) | 2017-06-05 | 2023-03-22 | PTC Therapeutics, Inc. | Compounds for treating huntington's disease |
| CN111372611A (zh) | 2017-06-14 | 2020-07-03 | Ptc医疗公司 | 修饰rna剪接的方法 |
| CN111182898B (zh) * | 2017-06-28 | 2024-04-16 | Ptc医疗公司 | 用于治疗亨廷顿氏病的方法 |
| CN111163838B (zh) | 2017-06-28 | 2023-03-28 | Ptc医疗公司 | 用于治疗亨廷顿氏病的方法 |
| MX2020001425A (es) | 2017-08-04 | 2020-08-06 | Skyhawk Therapeutics Inc | Metodos y composiciones para modular el empalme. |
| KR20260009385A (ko) | 2017-08-25 | 2026-01-19 | 스톡 테라퓨틱스, 인크. | 병태 및 질환 치료용 안티센스 올리고머 |
| HRP20251594T1 (hr) * | 2017-09-22 | 2026-01-30 | F. Hoffmann - La Roche Ag | Postupak priprave derivata 7-(4,7-diazaspiro[2.5]oktan-7-il)-2-(2,8-dimetilimidazo[1,2-b]piridazin-6-il)pirido[1,2-a]pirimidin-4-ona |
| LT3700570T (lt) | 2017-10-23 | 2025-04-10 | Stoke Therapeutics, Inc. | Priešprasmiai oligomerai, skirti būklių ir ligų, pagrįstų nonsens kodono nulemta mrnr degradacija, gydymui |
| BR112020019373A2 (pt) | 2018-03-27 | 2020-12-29 | Ptc Therapeutics, Inc. | Compostos para o tratamento da doença de hutington |
| JP2021523227A (ja) | 2018-05-04 | 2021-09-02 | ストーク セラピューティクス，インク． | コレステリルエステル蓄積症の処置のための方法及び組成物 |
| WO2020005882A1 (en) | 2018-06-27 | 2020-01-02 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| IL279688B2 (en) | 2018-06-27 | 2025-01-01 | Ptc Therapeutics Inc | Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease |
| WO2020004594A1 (ja) * | 2018-06-27 | 2020-01-02 | 株式会社リボルナバイオサイエンス | 脊髄性筋萎縮症の予防または治療剤 |
| KR20210038845A (ko) | 2018-06-27 | 2021-04-08 | 피티씨 테라퓨틱스, 인크. | 헌팅턴병 치료를 위한 헤테로아릴 화합물 |
| PT3830092T (pt) | 2018-08-03 | 2023-07-25 | Novartis Ag | Moduladores do recetor nmda heteroaromáticos e suas utilizações |
| US20210355509A1 (en) * | 2018-08-07 | 2021-11-18 | The Children's Hospital Of Philadelphia | Alternative splicing regulation of gene expression and therapeutic methods |
| WO2020163248A1 (en) | 2019-02-04 | 2020-08-13 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
| KR102913697B1 (ko) | 2019-02-05 | 2026-01-15 | 스카이호크 테라퓨틱스, 인코포레이티드 | 스플라이싱을 조절하는 방법 및 조성물 |
| WO2020163541A1 (en) | 2019-02-05 | 2020-08-13 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
| KR102925385B1 (ko) | 2019-02-06 | 2026-02-11 | 스카이호크 테라퓨틱스, 인코포레이티드 | 스플라이싱을 조절하는 방법 및 조성물 |
| JP7603594B2 (ja) | 2019-02-06 | 2024-12-20 | スカイホーク・セラピューティクス・インコーポレーテッド | スプライシングを調節するための方法および組成物 |
| KR20210134003A (ko) | 2019-02-27 | 2021-11-08 | 스톡 테라퓨틱스, 인크. | 병태 및 질환의 치료를 위한 안티센스 올리고머 |
| CA3139821A1 (en) | 2019-05-13 | 2020-11-19 | Ptc Therapeutics, Inc. | Compounds for treating huntington's disease |
| US11129829B2 (en) | 2019-06-17 | 2021-09-28 | Skyhawk Therapeutics, Inc. | Methods for modulating splicing |
| US12492214B2 (en) | 2019-07-31 | 2025-12-09 | Assia Chemical Industries Ltd. | Solid state forms of Risdiplam and process for preparation thereof |
| CN110540535B (zh) * | 2019-10-23 | 2020-07-31 | 上海再启生物技术有限公司 | 适合放大制备4-(6-氨基吡啶-3-基)取代哌啶的工艺方法 |
| CN111116576A (zh) * | 2019-12-01 | 2020-05-08 | 北京师范大学 | 一种喹嗪酮类化合物及其制备方法 |
| US12195458B2 (en) | 2019-12-02 | 2025-01-14 | Storm Therapeutics Limited | Polyheterocyclic compounds as METTL3 inhibitors |
| JP2023512116A (ja) | 2020-01-28 | 2023-03-23 | プロテゴ バイオファーマ， インコーポレイテッド | トランスサイレチンの安定化及びトランスサイレチンの誤った折り畳みの阻害のための化合物、組成物、及び方法 |
| CN115605596A (zh) * | 2020-02-12 | 2023-01-13 | 费城儿童医院（Us） | 用于基因表达的诱导型可变剪接调节的组合物和方法 |
| CA3169667A1 (en) | 2020-02-28 | 2021-09-02 | Dominic Reynolds | Pyridazine derivatives for modulating nucleic acid splicing |
| AU2021228284A1 (en) | 2020-02-28 | 2022-09-29 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| AU2021228285A1 (en) | 2020-02-28 | 2022-09-29 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| CA3169697A1 (en) | 2020-02-28 | 2021-09-02 | Dominic Reynolds | Thiophenyl derivatives useful for modulating nucleic acid splicing |
| AU2021225957A1 (en) | 2020-02-28 | 2022-09-08 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating SMN2 |
| MX2022012677A (es) | 2020-04-08 | 2023-01-11 | Remix Therapeutics Inc | Compuestos y metodos para modular el empalme. |
| CA3174353A1 (en) | 2020-04-08 | 2021-10-14 | Dominic Reynolds | Compounds and methods for modulating splicing |
| US12338437B2 (en) | 2020-05-11 | 2025-06-24 | Stoke Therapeutics, Inc. | OPA1 antisense oligomers for treatment of conditions and diseases |
| MX2023000168A (es) | 2020-07-02 | 2023-04-20 | Remix Therapeutics Inc | Derivados de 2-(indazol-5-il)-6-(piperidin-4-il)-1,7-naftiridina y compuestos relacionados como moduladores para el corte y empalme de ácidos nucleicos y para el tratamiento de enfermedades proliferativas. |
| EP4178963A1 (en) | 2020-07-02 | 2023-05-17 | Remix Therapeutics Inc. | 5-[5-(piperidin-4-yl)thieno[3,2-c]pyrazol-2-yl]indazole derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases |
| WO2022070071A1 (en) * | 2020-09-30 | 2022-04-07 | Janssen Biotech, Inc. | Dihydroorotate dehydrogenase inhibitors |
| CR20230437A (es) | 2021-03-17 | 2023-10-16 | Hoffmann La Roche | Nuevos derivados de tiazolopirimidinona |
| WO2023009585A2 (en) | 2021-07-28 | 2023-02-02 | Protego Biopharma, Inc. | Transthyretin stabilizing compounds |
| MX2024002554A (es) | 2021-08-30 | 2024-07-02 | Remix Therapeutics Inc | Compuestos y metodos para modular el empalme. |
| WO2023034827A1 (en) | 2021-08-30 | 2023-03-09 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| US20250333397A1 (en) | 2021-08-30 | 2025-10-30 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| US20240400584A1 (en) | 2021-08-30 | 2024-12-05 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| IL311135A (en) | 2021-08-30 | 2024-04-01 | Remix Therapeutics Inc | Compounds and methods for modulating splicing |
| US20250332173A1 (en) * | 2021-10-13 | 2025-10-30 | Remix Therapeutics Inc. | Compounds and methods for modulating nucleic acid splicing |
| TW202330552A (zh) | 2021-10-13 | 2023-08-01 | 美商雷密克斯醫療公司 | 調節剪接之化合物及方法 |
| US20250326748A1 (en) | 2022-01-05 | 2025-10-23 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| WO2023133217A1 (en) | 2022-01-05 | 2023-07-13 | Remix Therapeutics Inc. | 2-(indazol-5-yl)-6-(piperidin-4-yl)-1,7-naphthyridine derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases |
| WO2023133229A2 (en) | 2022-01-05 | 2023-07-13 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| WO2023240236A1 (en) | 2022-06-10 | 2023-12-14 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of spinal muscular atrophy related disorders |
| AU2024286618A1 (en) * | 2023-06-09 | 2025-10-30 | F. Hoffmann-La Roche Ag | Inducible gene expression system |
| CN117263936B (zh) * | 2023-11-21 | 2024-02-23 | 中国中医科学院医学实验中心 | 一种咪唑并[1, 2-a]吡啶衍生物及其制备方法和在中枢神经系统渗透性HDAC6抑制药物中的应用 |
| TW202608877A (zh) | 2024-05-07 | 2026-03-01 | 日商武田藥品工業股份有限公司 | 雜環化合物 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6977255B2 (en) * | 2000-01-24 | 2005-12-20 | Kinacia Pty. Ltd. | Therapeutic morpholino-substituted compounds |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3558618A (en) * | 1968-04-01 | 1971-01-26 | Dow Chemical Co | Novel 4h-pyrazino(1,2-a)pyrimidine-4-ones |
| US4122274A (en) * | 1977-05-25 | 1978-10-24 | Bristol-Myers Company | 3-Tetrazolo-5,6,7,8-substituted-pyrido[1,2-a]pyrimidin-4-ones |
| JPS56150091A (en) * | 1980-03-28 | 1981-11-20 | Janssen Pharmaceutica Nv | 3-(1-piperidinylalkyl)-4h-pyrido(1,2-a)pyrimidine- 4-one derivative and its manufacture |
| US4342870A (en) * | 1980-03-28 | 1982-08-03 | Janssen Pharmaceutica N.V. | Novel 3-(1-piperidinylalkyl)-4H-pyrido[1,2-a]pyrimidin-4-one derivatives |
| US5089633A (en) | 1987-04-28 | 1992-02-18 | Georgia Tech Research Corporation | Substituted isocoumarins |
| US5599816A (en) * | 1990-05-02 | 1997-02-04 | Abbott Laboratories | Quinolizinone type compounds |
| EP0640083A1 (en) * | 1992-05-13 | 1995-03-01 | E.I. Du Pont De Nemours And Company | Substituted pyrido 1,2-a]pyrimidinone derivatives as fungicides |
| KR19990022524A (ko) * | 1995-06-06 | 1999-03-25 | 웨인스톡 스티븐 에프. | 퀴놀리지논형화합물 |
| US5869500A (en) | 1996-12-13 | 1999-02-09 | Hoffmann-La Roche Inc. | Pyridone compounds useful in treating Alzheimer's disease |
| HK1040076A1 (zh) * | 1998-09-21 | 2002-05-24 | 希雷生物化学有限公司 | 作为整联蛋白抑制剂的喹嗪酮 |
| EP1227084B1 (en) * | 1999-10-28 | 2005-12-14 | Trine Pharmaceuticals, Inc. | Drug discharge pump inhibitors |
| JPWO2002087589A1 (ja) * | 2001-04-26 | 2004-08-12 | 第一製薬株式会社 | 薬剤排出ポンプ阻害薬 |
| ATE466581T1 (de) | 2001-12-07 | 2010-05-15 | Vertex Pharma | Verbindungen auf pyrimidin-basis als gsk-3-hemmer |
| GB0205281D0 (en) | 2002-03-06 | 2002-04-17 | Novartis Ag | Organic compounds |
| EP1542667B1 (en) | 2002-07-24 | 2012-03-07 | PTC Therapeutics, Inc. | Ureido substituted benzoic acid compounds and their use for nonsense suppression and the treatment of disease |
| ES2339862T3 (es) * | 2003-06-20 | 2010-05-26 | Novartis Vaccines And Diagnostics, Inc. | Compuestos de piridino 1,2-a-pirimidin-4-ona como agentes anticancerosos. |
| WO2005105801A1 (en) | 2004-05-04 | 2005-11-10 | Warner-Lambert Company Llc | Pyrrolyl substituted pyrido[2,3-d]pyrimidin-7-ones and derivatives thereof as therapeutic agents |
| US7399767B2 (en) | 2005-01-21 | 2008-07-15 | Ortho-Mcneil Pharmaceutical, Inc. | Heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors |
| AR059339A1 (es) | 2006-02-09 | 2008-03-26 | Chugai Pharmaceutical Co Ltd | Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene |
| US8110681B2 (en) * | 2006-03-17 | 2012-02-07 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Compounds for the treatment of spinal muscular atrophy and other uses |
| US8337941B2 (en) | 2006-07-27 | 2012-12-25 | The Trustees Of Columbia University In The City Of New York | Fluorescent substrates for monoamine transporters as optical false neurotransmitters |
| US8633019B2 (en) | 2008-05-27 | 2014-01-21 | Ptc Therapeutics, Inc. | Methods for treating spinal muscular atrophy |
| EP2138493A1 (en) * | 2008-06-26 | 2009-12-30 | Sanofi-Aventis | Substituted pyrimidone derivatives |
| WO2010019236A1 (en) | 2008-08-13 | 2010-02-18 | Ptc Therapeutics, Inc | Methods for treating spinal muscular atrophy |
| WO2011050245A1 (en) * | 2009-10-23 | 2011-04-28 | Yangbo Feng | Bicyclic heteroaryls as kinase inhibitors |
| EP2501231B1 (en) | 2009-11-20 | 2016-12-21 | Merck Sharp & Dohme Corp. | Quinolizidinone carboxamide m1 receptor positive allosteric modulators |
| KR20130088002A (ko) | 2010-01-13 | 2013-08-07 | 재단법인 한국파스퇴르연구소 | 항-감염성 피리도(1,2-ａ)피리미딘 |
| MX352861B (es) | 2011-12-30 | 2017-12-13 | Ptc Therapeutics Inc | Compuestos para tratar la atrofia muscular espinal. |
| MX357834B (es) | 2012-01-26 | 2018-07-26 | Ptc Therapeutics Inc | Compuestos de tipo isocumarina sustituidos para tratar la atrofia muscular espinal. |
| EP3406252B1 (en) * | 2012-02-10 | 2020-05-13 | PTC Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
| US9371336B2 (en) | 2012-03-01 | 2016-06-21 | Ptc Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
| EP2828247B1 (en) | 2012-03-23 | 2019-01-16 | PTC Therapeutics, Inc. | 4h-chromen-4-one derivatives for treating spinal muscular atrophy |
| AU2015261046C1 (en) | 2014-05-15 | 2019-07-25 | F. Hoffmann-La Roche Ag | Compounds for treating spinal muscular atrophy |
| EP3298017B1 (en) | 2015-05-20 | 2019-08-14 | H. Hoffnabb-La Roche Ag | Compounds for treating spinal muscular atrophy |
-
2013
- 2013-02-08 EP EP18179491.8A patent/EP3406252B1/en active Active
- 2013-02-08 AU AU2013216870A patent/AU2013216870B2/en active Active
- 2013-02-08 SG SG11201404713PA patent/SG11201404713PA/en unknown
- 2013-02-08 KR KR1020147025275A patent/KR102137087B1/ko active Active
- 2013-02-08 KR KR1020207020788A patent/KR102341596B1/ko active Active
- 2013-02-08 EP EP13747100.9A patent/EP2812004B1/en active Active
- 2013-02-08 SG SG10201609188WA patent/SG10201609188WA/en unknown
- 2013-02-08 UA UAA201409921A patent/UA116981C2/uk unknown
- 2013-02-08 EA EA201491505A patent/EA029542B1/ru not_active IP Right Cessation
- 2013-02-08 PL PL13747100T patent/PL2812004T3/pl unknown
- 2013-02-08 EA EA201792465A patent/EA037123B1/ru unknown
- 2013-02-08 HU HUE13747100A patent/HUE039779T2/hu unknown
- 2013-02-08 JP JP2014556711A patent/JP6092897B2/ja active Active
- 2013-02-08 TR TR2018/13877T patent/TR201813877T4/tr unknown
- 2013-02-08 CN CN201810234432.7A patent/CN108299314B/zh active Active
- 2013-02-08 PE PE2014001250A patent/PE20142364A1/es active IP Right Grant
- 2013-02-08 PH PH1/2018/501711A patent/PH12018501711B1/en unknown
- 2013-02-08 BR BR112014019750-4A patent/BR112014019750B1/pt active IP Right Grant
- 2013-02-08 ES ES13747100T patent/ES2697174T3/es active Active
- 2013-02-08 DK DK13747100.9T patent/DK2812004T3/en active
- 2013-02-08 NZ NZ628186A patent/NZ628186A/en unknown
- 2013-02-08 MX MX2014009696A patent/MX354074B/es active IP Right Grant
- 2013-02-08 CA CA2863874A patent/CA2863874C/en active Active
- 2013-02-08 CN CN202411603136.1A patent/CN119528903A/zh active Pending
- 2013-02-08 CN CN201380019368.6A patent/CN104349777B/zh active Active
- 2013-02-08 WO PCT/US2013/025292 patent/WO2013119916A2/en not_active Ceased
- 2013-02-08 US US14/377,531 patent/US9586955B2/en active Active
- 2013-02-14 AR ARP130100450 patent/AR092794A1/es active IP Right Grant
- 2013-02-18 TW TW102105672A patent/TWI585085B/zh active
- 2013-02-18 TW TW106106161A patent/TWI629274B/zh active
-
2014
- 2014-08-05 IL IL233959A patent/IL233959A/en active IP Right Grant
- 2014-08-07 PH PH12014501786A patent/PH12014501786A1/en unknown
- 2014-08-08 CL CL2014002100A patent/CL2014002100A1/es unknown
- 2014-08-08 CR CR20140376A patent/CR20140376A/es unknown
- 2014-08-11 MX MX2022011699A patent/MX2022011699A/es unknown
- 2014-08-28 MA MA37313A patent/MA35920B1/fr unknown
- 2014-09-04 EC ECIEPI201417269A patent/ECSP14017269A/es unknown
- 2014-09-09 CO CO14198817A patent/CO7061082A2/es unknown
-
2016
- 2016-08-26 US US15/248,052 patent/US9879007B2/en active Active
-
2017
- 2017-02-09 JP JP2017022640A patent/JP6363744B2/ja active Active
- 2017-06-22 AU AU2017204248A patent/AU2017204248B2/en active Active
- 2017-08-17 IL IL254045A patent/IL254045B/en active IP Right Grant
- 2017-12-20 US US15/848,075 patent/US20180105526A1/en not_active Abandoned
-
2019
- 2019-08-15 US US16/541,401 patent/US10851101B2/en active Active
-
2020
- 2020-10-05 US US17/062,853 patent/US11753407B2/en active Active
-
2023
- 2023-07-26 US US18/359,209 patent/US20240067646A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6977255B2 (en) * | 2000-01-24 | 2005-12-20 | Kinacia Pty. Ltd. | Therapeutic morpholino-substituted compounds |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240067646A1 (en) | Compounds for treating spinal muscular atrophy | |
| EP2809322B9 (en) | Compounds for treating spinal muscular atrophy | |
| WO2013130689A1 (en) | Compounds for treating spinal muscular atrophy | |
| EP2828247A1 (en) | Compounds for treating spinal muscular atrophy | |
| BR112014016443B1 (pt) | Mistura de pó e método de fabricação de um componente sinterizado | |
| HK40005163B (en) | Compounds for treating spinal muscular atrophy | |
| HK40005163A (en) | Compounds for treating spinal muscular atrophy | |
| HK1202077B (en) | Compounds for treating spinal muscular atrophy | |
| HK1202069B (en) | Compounds for treating spinal muscular atrophy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ QI, HONGYAN; CHOI, SOONGYU; DAKKA, AMAL; KARP, GARY MITCHELL; NARASIMHAN, JANA; NARYSHKIN, NIKOLAI; TURPOFF, ANTHONY A.; WEETALL, MARLA L.; WELCH, ELLEN; WOLL, MATTHEW G.; YANG, TIANLE; ZHANG, NANJING; ZHANG, XIAOYAN; ZHAO, XIN; GREEN, LUKE; PINARD, EMMANUEL AND RATNI, HASANE |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| NC | Extension of term for standard patent requested (sect. 70) |
Free format text: PRODUCT NAME: EVRYSDI RISDIPLAM Filing date: 20210602 |
|
| NDA | Extension of term for standard patent accepted (sect.70) |
Free format text: PRODUCT NAME: EVRYSDI RISDIPLAM Filing date: 20210602 |
|
| NDB | Extension of term for standard patent granted (sect.76) |
Free format text: PRODUCT NAME: EVRYSDI RISDIPLAM Filing date: 20210602 Extension date: 20360602 |